NCCN Guidelines Insights: Breast Cancer, Version 3.2018.

Journal Article (Journal Article)

These NCCN Guidelines Insights highlight the updated recommendations for use of multigene assays to guide decisions on adjuvant systemic chemotherapy therapy for women with hormone receptor-positive, HER2-negative early-stage invasive breast cancer. This report summarizes these updates and discusses the rationale behind them.

Full Text

Duke Authors

Cited Authors

  • Goetz, MP; Gradishar, WJ; Anderson, BO; Abraham, J; Aft, R; Allison, KH; Blair, SL; Burstein, HJ; Dang, C; Elias, AD; Farrar, WB; Giordano, SH; Goldstein, LJ; Isakoff, SJ; Lyons, J; Marcom, PK; Mayer, IA; Moran, MS; Mortimer, J; O'Regan, RM; Patel, SA; Pierce, LJ; Reed, EC; Rugo, HS; Sitapati, A; Smith, KL; Smith, ML; Soliman, H; Telli, ML; Ward, JH; Young, JS; Shead, DA; Kumar, R

Published Date

  • February 2019

Published In

Volume / Issue

  • 17 / 2

Start / End Page

  • 118 - 126

PubMed ID

  • 30787125

Electronic International Standard Serial Number (EISSN)

  • 1540-1413

Digital Object Identifier (DOI)

  • 10.6004/jnccn.2019.0009


  • eng

Conference Location

  • United States